Back to Research

Organization profile

LeadXpro

LeadXpro is a specialist organization in structure-based drug discovery (SBDD) focused on "unlocking" membrane proteins like GPCRs, ion channels, and transporters. The company utilizes advanced biophysics, Cryo-EM, and synchrotron-based technologies to accelerate the development of novel medicines for unmet medical needs.

Villigen, SwitzerlandFounded 2015

Overview

1. Executive Summary (Confidence: High)

LeadXpro AG, founded in 2015 and headquartered at the Paul Scherrer Institute (PSI) in Switzerland, is a preeminent leader in membrane protein research.[23] Membrane proteins are the targets for over 50% of marketed drugs, yet they are notoriously difficult to characterize due to their instability outside the cell membrane.[24] LeadXpro has solved this "insurmountable" challenge by combining proprietary target stabilization with world-class structural biology tools, including the Swiss Free Electron Laser (SwissFEL) and advanced Cryo-EM.[24] As of 2024, the company has established protein science for more than 100 drug targets and has moved multiple programs into the hit-to-lead stage through collaborations with companies like Cumulus Oncology and Golgi Neurosciences.[23] In early 2026, the company entered a transformative partnership with Nuclera to integrate AI-guided workflows into its platform, further accelerating the timeline from protein sequence to structural insights.[25]

This is an extract of the full organization profile. To access the full company profile, .

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.